NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Volumetric CT in Lung Cancer: An Example for the Qualification of Imaging as a Biomarker
Published
Author(s)
Charles D. Fenimore, Andrew Buckler, P. David Mozeley, Lawrence H. Schwartz, Nicholas Petrick, Michael McNitt-Gray, Kevin O?Donnell, Wendy Hayes, Hyun Kim, Laurence Clarke, Daniel Sullivan
Abstract
The Quantitative Imaging Biomarker Alliance (QIBA) has been organized to establish a methodology whereby multiple stakeholders collaborate to test hypotheses about the technical feasibility and the medical value of imaging biomarkers. It has charged the Volumetric Computed Tomography (CT) Technical Subcommittee with investigating the technical feasibility and clinical value of quantifying changes over time in either volume or other parameters. Lung cancer was selected as the first example. Success will be defined as sufficiently rigorous improvements in CT-based outcome measures to (1) allow individual patients in clinical settings to switch treatments sooner if they are no longer responding to their current regimens, and (2) reduce the costs of evaluating investigational new drugs to treat lung cancer. This mechanism is cost-effective for stakeholders while simultaneously advancing the public health by advancing the use of measures which prove effective. If the specific aims are achieved in the example, then the paradigm will be extrapolated to other clinical scenarios where increasingly powerful imaging biomarkers across modalities become medically meaningful.
Fenimore, C.
, Buckler, A.
, , P.
, Schwartz, L.
, Petrick, N.
, McNitt-Gray, M.
, O?Donnell, K.
, Hayes, W.
, Kim, H.
, Clarke, L.
and Sullivan, D.
(2010),
Volumetric CT in Lung Cancer: An Example for the Qualification of Imaging as a Biomarker, Academic Radiology, [online], https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=902417
(Accessed October 11, 2025)